Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE 80 25 versus TRICHLORMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE 80 25 versus TRICHLORMETHIAZIDE.
INDERIDE-80/25 vs TRICHLORMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
2-4 mg orally once daily; maximum 4 mg/day.
None Documented
None Documented
Clinical Note
moderateTrichlormethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin."
Clinical Note
moderateTrichlormethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin."
Clinical Note
moderateTrichlormethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside."
Clinical Note
moderatePropranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
Terminal elimination half-life is approximately 2-6 hours (average 3.5 h); clinical context: short half-life necessitates once or twice daily dosing for sustained diuresis.
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Primarily renal (tubular secretion); ~70% excreted unchanged in urine; minor biliary/fecal (<10% total).
Category C
Category C
Beta Blocker and Thiazide Diuretic
Thiazide Diuretic
Trichlormethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Acetyldigitoxin."